NCT04957147View on ClinicalTrials.gov

Reverse Remodelling and Remission Markers in the Serial Evaluation of Recent-onset Dilated Cardiomyopathy

CompletedOBSERVATIONAL

Enrollment

103

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions

Dilated Cardiomyopathy

Interventions

OTHER

12 months of guideline-directed heart failure therapy

Standard guideline-directed heart failure drug +/- device therapy

Trial Locations (1)

SW3 6LY

Imperial College, London

All Listed Sponsors

collaborator

Royal Brompton & Harefield NHS Foundation Trust

OTHER

lead

Imperial College London

OTHER

NCT04957147 - Reverse Remodelling and Remission Markers in the Serial Evaluation of Recent-onset Dilated Cardiomyopathy | Biotech Hunter | Biotech Hunter